首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Integrated flow-through purification for therapeutic monoclonal antibodies processing
Authors:Takamitsu Ichihara  Yasuhiko Kurisu  Kevin Galipeau  Christopher Gillespie
Institution:1. Astellas Pharma Inc. 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan;2. Process solutions, Merck Ltd., DiverCity Tokyo Office Tower 15F, 1-1-20 Aomi, Koto-ku, Tokyo, Japan;3. Process solutions, MilliporeSigma, Bedford MA, USA
Abstract:An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to have excellent impurity clearance at high mAb loadings with overall mAb yield exceeding 80%. Robust removal of DNA and host cell protein was demonstrated by activated carbon and a new flow-through cation exchange resin exhibited excellent clearance of mAb aggregate with high monomer recoveries. A ten-fold improvement of mAb loading was achieved compared to a traditional cation exchange resin designed for bind and elute mode. High throughput 96-well plate screening was used for process optimization, focusing on mAb loading and solution conditions. Optimum operating windows for integrated flow-through purification are proposed based on performance characteristics. The combination of an all flow-through polishing process presents significant opportunities for improvements in facility utilization and process economics.
Keywords:activated carbon  continuous manufacturing  flow-through chromatography  integrated process  monoclonal antibody  purification
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号